Full Text View
Tabular View
No Study Results Posted
Related Studies
A Study of the Safety of Rabeprazole Administered to Adults With Gastroesophageal Reflux Disease (GERD)
This study has been completed.
Study NCT00216489   Information provided by Janssen Cilag Pharmaceutica S.A.C.I., Greece

First Received on September 13, 2005.   Last Updated on April 22, 2010   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Gastroesophageal Reflux
Heartburn
More general conditions related to this trial
Deglutition Disorders
Digestive System Diseases
Esophageal Diseases
Esophageal Motility Disorders
Gastrointestinal Diseases
Signs and Symptoms
Signs and Symptoms, Digestive
Interventions listed in this trial
rabeprazole sodium
Additional drug interventions recognized in this trial
Proton Pump Inhibitors
Rabeprazole
More general drug interventions related to this trial
Anti-Ulcer Agents
Enzyme Inhibitors
Gastrointestinal Agents
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Therapeutic Uses
Sponsors listed in this trial
Janssen Cilag Pharmaceutica S.A.C.I., Greece


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services